Clinical Trials

Numerous clinical trials evaluate uric acid and urate-related physiological pathways across conditions including hyperuricemia, gout, uric acid nephrolithiasis, hypertension, and metabolic disorders. Spanning Early Phase 1 through Phase 4 alongside unassigned interventional studies, these protocols—encompassing active, recruiting, completed, and withdrawn statuses—are sponsored by major academic and clinical institutions such as Johns Hopkins University and Seoul National University Hospital. Specific interventions assessed include dietary regimens for elevated serum urate, probiotic supplementation for gout, and urinary alkalinization for urate stone management.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT07613164 NOT_YET_RECRUITING
Hyperuricemia, Gout
Maanshan Shiqiye Hospital
2026-05
NCT07326839 NOT_YET_RECRUITING
Gout; Obesity
XueMei Guo
2025-12-10
NCT07650214 NOT_YET_RECRUITING
Asymptomatic Hyperuricemia
Sun Yat-sen University
2026-07-01
NCT04026776 RECRUITING
Salt; Excess; Blood Pressure Disorders
Wake Forest University Health Sciences
2020-09-02 EARLY_PHASE1
NCT06824376 RECRUITING
Asymptomatic Hyperuricemia
Shenghao Tu
2025-03-25
NCT06335537 RECRUITING
Uric Acid Stones
University of California, Irvine
2025-05-01 PHASE1
NCT04745910 COMPLETED
Hematopoietic and Lymphoid Cell Neoplasm; Malignant Solid Neoplasm; Tumor Lysis Syndrome
M.D. Anderson Cancer Center
2022-04-05 PHASE4
NCT06966635 RECRUITING
Hyperuricemia or Gout; Nephrolithiasis
Huashan Hospital
2024-04-10 PHASE4
NCT07076888 RECRUITING
Hemodialysis
Cairo University
2025-08-01
NCT06187519 COMPLETED
Gout
University of California, Los Angeles
2025-03-10
NCT04370093 COMPLETED
Nephrolithiasis, Uric Acid
University of Texas Southwestern Medical Center
2019-10-17 PHASE4
NCT04621929 COMPLETED
Obesity; Uric Acid Stones; Type 2 Diabetes Mellitus in Obese; Pre-Diabetes
University of Florida
2021-03-31 PHASE2
NCT06621589 COMPLETED
Obesity
RS H Adam Malik
2024-08-26
NCT05298891 Not yet recruiting
Acromegaly
Azienda Ospedaliero Universitaria Maggiore della Carita
2024-09-01 Not Applicable
NCT05745727 COMPLETED
Gout
Protalix
2023-03-23 PHASE1
NCT06126315 Not yet recruiting
Amyotrophic Lateral Sclerosis
Mario Negri Institute for Pharmacological Research|University of Sydney|FightMND
2024-06 Phase 2|Phase 3
NCT06177821 Recruiting
Prostatic Hyperplasia of the Medial Lobe
Seoul National University Hospital
2024-06-03 Not Applicable
NCT06335537 Not yet recruiting
Uric Acid Stones
University of California Irvine
2024-05 Phase 1
NCT06084585 UNKNOWN
Hyperuricemia
Amway (China) R&D Center
2023-10-23
NCT05402397 COMPLETED
Uric Acid Nephropathy
Hospital General de Niños Pedro de Elizalde
2022-07-01 PHASE4
NCT05496075 COMPLETED
Uric Acid
Shanghai 10th People's Hospital
2022-08-26 PHASE4
NCT04199325 UNKNOWN
Gout; Hyperuricemia
The Affiliated Hospital of Inner Mongolia Medical University
2018-11-01
NCT03899883 COMPLETED
Diabetic Kidney Disease; Hyperuricemia; Diabetes; Diabetes Mellitus, Type 2; Type2 Diabetes; Type 2 Diabetes Mellitus; Diabetic Nephropathies; Diabetes Complications
University of Colorado, Denver
2020-01-01 PHASE2
NCT04316390 COMPLETED
Higher Uric Acid Concentrations (>5,5 mg/dl); Healthy
University of Kiel
2022-07-15
NCT05226013 UNKNOWN
Hyperuricemia
The Affiliated Hospital of Qingdao University
2021-12-08 PHASE1
NCT04772313 COMPLETED
Uncontrolled Gout
Amgen
2021-03-08 PHASE4
NCT03648996 COMPLETED
Diabetes Mellitus, Type 2; Hyperuricemia
University of Missouri-Columbia
2018-11-01 PHASE2
NCT04960527 COMPLETED
Uric Acid; Cardiovascular Diseases; Gout
Sheffield Hallam University
2021-07-10
NCT04772352 UNKNOWN
Nonalcoholic Fatty Liver Disease
Ningbo No. 1 Hospital
2021-03-01 PHASE2
NCT05210517 COMPLETED
Type 2 Diabetes
Amsterdam UMC, location VUmc
2020-10-01 PHASE4
NCT04837274 COMPLETED
Health Services Research
Texas A&M University
2020-04-10
NCT03865407 TERMINATED
Hyperuricemia; Chronic Kidney Diseases
Virginia Commonwealth University
2019-03-10 PHASE2
NCT05967754 COMPLETED
Obstructive Sleep Apnea
Alexandria University
2018-01-01
NCT04352153 UNKNOWN
Uric Acid Stones; Hyperuricemia
Ai Peng
2020-04-01
NCT02975986 WITHDRAWN
Uric Acid Nephrolithiasis
University of Texas Southwestern Medical Center
2017-01
NCT04165499 COMPLETED
Hyperuricemia
Biosearch S.A.
2019-11-11 EARLY_PHASE1
NCT03395977 COMPLETED
Oxidative Stress; Endothelial Function; Cardiovascular System; Hypertension
Erasme University Hospital
2018-01-03
NCT02891031 UNKNOWN
Hyperuricemia
Shiraz University of Medical Sciences
2019-06-01
NCT03569020 COMPLETED
Gout; Hyperuricemia
Johns Hopkins University
2018-08-07
NCT03403309 COMPLETED
Multiple System Atrophy
Yonsei University
2018-05-02 PHASE2
NCT03658317 UNKNOWN
Diabetic Nephropathy
Assiut University
2018-09
NCT03226899 TERMINATED
Gout; Chronic Kidney Disease (CKD)
Ironwood Pharmaceuticals, Inc.
2017-07-19 PHASE4
NCT03939130 COMPLETED
Fructose Metabolism Disorder; Fructose Rich Diet; Metabolic Disease; Aerobic Exercise
Federal University of Rio Grande do Sul
2018-06-01
NCT03076684 WITHDRAWN
Hyperuricemia
University of Missouri-Columbia
2017-03-03 EARLY_PHASE1
NCT02959918 COMPLETED
Gout Chronic; Hyperuricemia
Selecta Biosciences, Inc.
2016-10 PHASE2
NCT03118739 COMPLETED
Hyperuricemia; Albuminuria; Type 2 Diabetes
AstraZeneca
2017-05-18 PHASE2
NCT03306758 UNKNOWN
Asymptomatic Hyperuricemia; Gout
Shanghai Zhongshan Hospital
2017-11-01
NCT03316131 COMPLETED
Asymptomatic Hyperuricemia
AstraZeneca
2017-10-25 PHASE2
NCT03568864 COMPLETED
Healthy
University of Exeter
2017-07-31
NCT03211403 COMPLETED
Gout; Hyperuricemia
Atridia Pty Ltd.
2017-07-04 PHASE1
NCT02129764 COMPLETED
Heart Failure, Hyperuricemia
Hebei Medical University
2013-12 PHASE2; PHASE3
NCT02644486 TERMINATED
Obesity and Glomerulopathy
Zhi-Hong Liu, M.D.
2016-01
NCT03531203 COMPLETED
Blood Pressure; Prehypertension; Uric Acid
Gadjah Mada University
2017-07-10
NCT03218709 UNKNOWN
Hyperuricemia
Sun Yat-sen University
2017-01 PHASE4
NCT02984358 COMPLETED
Healthy
University of Exeter
2017-01
NCT00904046 COMPLETED
Uric Acid Kidney Stone Disease
University of Texas Southwestern Medical Center
2010-01-15
NCT03512600 COMPLETED
Lithiasis, Urinary
Devicare S.L.
2017-09-04
NCT02563405 UNKNOWN
Hypertension
First Affiliated Hospital of Harbin Medical University
2015-09 PHASE2; PHASE3
NCT02502071 COMPLETED
Type 1 Diabetes; Diabetic Nephropathy; Diabetic Kidney Disease
University of Colorado, Denver
2017-01 PHASE4
NCT02648269 COMPLETED
Gout
Selecta Biosciences, Inc.
2015-12 PHASE1
NCT02797028 UNKNOWN
Cardiovascular Disease
Guangzhou General Hospital of Guangzhou Military Command
2015-01 PHASE4
NCT01228903 COMPLETED
Kidney Disease
University of Colorado, Denver
2010-10
NCT02561858 COMPLETED
Uric Acid Stones
Centre Hospitalier Universitaire de Nice
2015-10-14
NCT02464605 COMPLETED
Gout
Selecta Biosciences, Inc.
2015-05 PHASE1
NCT02344602 COMPLETED
Type 1 Diabetes Mellitus
University Health Network, Toronto
2012-12-18 PHASE4
NCT02063997 COMPLETED
Gout
Gilead Sciences
2014-03 PHASE2
NCT01510769 COMPLETED
Tophaceous Gout
Ardea Biosciences, Inc.
2012-01 PHASE3
NCT01881919 COMPLETED
Hyperuricemia; Gout; Kidney Calculi; Diabetes; Cardiovascular Disease
University of Leeds
2013-02 EARLY_PHASE1
NCT01472692 COMPLETED
Prehypertension; Gout; Pulse Wave Velocity; Hypertension; 24 Hour Blood Pressure
University of California, San Diego
2011-10 PHASE4
NCT01323335 COMPLETED
Healthy Volunteers
National Institute on Aging (NIA)
2009-03-31 PHASE1
NCT01532622 COMPLETED
Hyperuricemia
University of Mississippi Medical Center
2012-01
NCT00860366 COMPLETED
Acute Ischemic Stroke
Angel Chamorro, MD
2011-06 PHASE2; PHASE3
NCT01797042 COMPLETED
Obesity
Rippe Lifestyle Institute
2012-03
NCT01363869 COMPLETED
Hyperuricemia; Gout
Chiang Mai University
2011-06
NCT01407874 COMPLETED
Gout; Hyperuricemia; Arthritis; Joint Disease; Renal Insufficiency
BioCryst Pharmaceuticals
2011-09 PHASE2
NCT01825070 COMPLETED
Inflammation
Northumbria University
2012-03
NCT00241839 COMPLETED
Cardiovascular Diseases; Heart Diseases; Hypertension
University of Florida
2005-08 PHASE3
NCT04954560 COMPLETED
Uric Acid Concentration, Serum, Quantitative Trait Locus 7
Medical University of Lodz
2008-01-01
NCT00868673 COMPLETED
Overweight and Obesity; Metabolic Syndrome; Hyperuricemia
Instituto Nacional de Cardiologia Ignacio Chavez
2009-03
NCT00793585 COMPLETED
IgA Nephropathy
Sun Yat-sen University
2007-07
NCT00978653 COMPLETED
Hyperuricemia; Chronic Kidney Disease
Istanbul University
2008-04
NCT00738842 COMPLETED
Gout; Coronary Artery Disease
AstraZeneca
2008-05 PHASE1
NCT01931527 COMPLETED
Obesity; Metabolic Syndrome; Hyperuricemia
Washington University School of Medicine
2006-07
NCT00230178 COMPLETED
Tumor Lysis Syndrome; Cancer; Hyperuricemia
Sanofi
2004-04 PHASE3
NCT03921736 COMPLETED
Hypertension; Hyperuricemia; Menopause
Anna Posadzy-Małaczyńska
2000-01-10 PHASE4
NCT00474396 COMPLETED
Healthy
Icahn School of Medicine at Mount Sinai
2005-04

(data from https://clinicaltrials.gov, updated on 2026-05-29)

Check the Uric Acid product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Uric acid functions as an end-stage product of purine catabolism that, at elevated systemic concentrations, precipitates into monosodium urate crystals that engage cell membrane surface elements to activate the intracellular NLRP3 inflammasome signaling complex. This cascade triggers downstream interleukin-1beta release and reactive oxygen species accumulation, inducing local tissue inflammation and endothelial damage that directly underlie clinical trial conditions such as hyperuricemia, gout, and urinary lithiasis.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.